100120.KQ
Vieworks Co., Ltd.
KOE · Healthcare · Medical - Devices · KR
KRW 26,200.00
−2.06%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 244.3B | 239.3B | 222.9B | 220.3B | 237.9B |
| Cost of Revenue | 136.6B | 142.4B | 127.3B | 125.0B | 131.5B |
| Gross Profit | 107.7B | 96.9B | 95.6B | 95.3B | 106.4B |
| Operating Expenses | |||||
| R&D Expense | 18.3B | 25.9B | 26.1B | 26.9B | 22.8B |
| SG&A Expense | 15.6B | 21.3B | 20.1B | 18.1B | 16.6B |
| General & Admin Expense | 4.4B | 5.9B | 5.8B | 5.0B | 4.9B |
| Selling & Marketing Expense | 11.1B | 15.3B | 14.3B | 13.1B | 11.7B |
| Other Expenses | 49.5B | 28.5B | 27.1B | 31.6B | 24.7B |
| Total Operating Expenses | 75.4B | 75.6B | 73.3B | 76.6B | 64.1B |
| Cost and Expenses | 211.9B | 217.9B | 200.6B | 201.5B | 195.6B |
| Operating Income (EBIT) | 32.4B | 21.4B | 20.9B | 18.7B | 43.7B |
| Non-Operating | |||||
| Interest Income | 1.1B | 1.4B | 1.0B | 345.3M | 168.4M |
| Interest Expense | 2.3B | 1.4B | 2.3B | 2.5B | 1.1B |
| Net Interest Income | (1.2B) | (14.4M) | (1.3B) | (2.1B) | (904.9M) |
| Other Non-Op Income/Expense | 15.8B | 3.9B | 4.7B | (1.7B) | (10.6B) |
| Non-Operating Income (excl Interest) | (7.5B) | — | (5.6B) | (432.5M) | 7.8B |
| EBT (Pre-Tax Income) | 48.3B | 25.3B | 25.6B | 17.0B | 33.1B |
| Income Tax Expense | 5.9B | 4.4B | 4.5B | 1.9B | 6.6B |
| Bottom Line | |||||
| Net Income | 43.5B | 22.0B | 21.3B | 14.7B | 26.5B |
| Earnings from Cont. Ops | 42.4B | 20.9B | 21.1B | 14.8B | 26.5B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 43.5B | 22.0B | 21.3B | 14.7B | 26.5B |
| Per Share | |||||
| Basic EPS | ₩4,838 | ₩2,434 | ₩2,317 | ₩1,603 | ₩2,890 |
| Diluted EPS | ₩4,838 | ₩2,434 | ₩2,319 | ₩1,603 | ₩2,890 |
| Revenue Per Share | ₩27,521 | ₩25,570 | ₩24,276 | ₩23,987 | ₩25,913 |
| Shares | |||||
| Basic Shares Outstanding | 8.9M | 9.4M | 9.2M | 9.2M | 9.2M |
| Diluted Shares Outstanding | 8.9M | 9.4M | 9.2M | 9.2M | 9.2M |
| Profitability Metrics | |||||
| EBITDA | 44.2B | 29.7B | 35.4B | 26.2B | 40.7B |
| D&A | 8.3B | 8.3B | 7.4B | 7.0B | 6.1B |
| EBIT | 35.9B | 21.2B | 27.9B | 19.2B | 34.5B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026